Paper - WANFANG MED ONLINE

You Position: Home > Paper

肺癌免疫检查点抑制剂治疗的不良反应及其防治

( views:78, downloads:2285 )

Author:: No author available

Journal Title:: Chinese Journal of Tuberculosis and Respiratory Diseases

Issue:: 2

DOI:: 10.3760/cma.j.issn.1001-0939.2020.02.005

Key Word:: No keyword available

Abstract：肺癌免疫检查点抑制剂(主要为抗PD-1或PD-L1类药物)可显著提升晚期肺癌患者的5年生存率,目前在晚期肺癌一线及二线治疗中占据重要地位,未来将成为肺癌治疗的主要措施之一,而呼吸领域的临床医生对其不良反应还缺乏足够的认识.本文简要介绍肺癌免疫检查点抑制剂治疗的不良反应及其防治.

Reference

[1]李珊,孙宇新,黄慧,等.免疫检查点抑制剂相关性间质性肺疾病的诊疗进展[J].2018,(12).
[2]Flaherty Keith,Fadden Riley,Rubin Krista,etc.High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma[J].2018,124(18).
[3]I, Puzanov,A, Diab,K, Abdallah,etc.Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.[J].2017,5(1).
[4]Dwight H,Owen,Lai,Wei,Erin M,Bertino,etc.Incidence, Risk Factors, and Effect on Survival of Immune-related Adverse Events in Patients With Non-Small-cell Lung Cancer.[J].2018.
[5]Vivek, Kumar,Neha, Chaudhary,Mohit, Garg,etc.Corrigendum: Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy.[J].2017,8(Spec ).
[6]Larkin, J.,Chiarion-Sileni, V.,Gonzalez, R.,etc.Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma[J].2015,373(1).
[7]Jordi, Remon,Laura, Mezquita,Jesús, Corral,etc.Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: focusing on non-small cell lung cancer patients.[J].2017,10(Suppl 13).
[8]Delaunay, Myriam,Cadranel, Jacques,Lusque, Amelie,etc.Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients[J].2017,50(2).
[9]Naidoo, J.,Page, D. B.,Li, B. T.,etc.Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies[J].2015,26(12).
[10]Peyton Cramer,Robert S. Bresalier.Gastrointestinal and Hepatic Complications of Immune Checkpoint Inhibitors[J].2017,19(1).
[11]Emanuela Rossi,Assunta Sgambato,Giovanni De Chiara,etc.Endocrinopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancer[J].2016,9(1).
[12].Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer: A Systematic Review and Meta-analysis.[J].2016,(12).
[13]Reck, Martin,Rodriguez-Abreu, Delvys,Robinson, Andrew G.,etc.Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer[J].2016,375(19).
[14]Romualdo, Barroso-Sousa,William T, Barry,Ana C, Garrido-Castro,etc.Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.[J].2017,(Spec ).
[15]Suzanne L Topalian,Mario Sznol,David F McDermott,etc.Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.[J].2014,32(10).
[16].New NCCN Guidelines: Recognition and Management of Immunotherapy-Related Toxicity.[J].2018,16(5S).
[17]Fehrenbacher, Louis,Spira, Alexander,Ballinger, Marcus,etc.Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial[J].2016,387(10030).
[18]David S, Ettinger,Dara L, Aisner,Douglas E, Wood,etc.NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018.[J].2018,16(7).
[19]Rittmeyer, Achim,Barlesi, Fabrice,Waterkamp, Daniel,etc.Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial[J].2017,389(10066).
[20]Jun,Tang,Jia Xin,Yu,Vanessa M,Hubbard-Lucey,etc.Trial watch: The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors.[J].2018,17(12).
[21]Haanen, J. B. A. G.,Larkin, J.,Jordan, K.,etc.Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J].2017,28(Suppl.4).
[22]Herbst, Roy S.,Baas, Paul,Kim, Dong-Wan,etc.Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial[J].2016,387(10027).
[23]Horn, Leora,Geese, William J.,Spigel, David,etc.Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study[J].2018,36(17).
[24]Moslehi, Javid J.,Johnson, Douglas B.,Sosman, Jeffrey A..Myocarditis with Immune Checkpoint Blockade.[J].2017,376(3).
[25]Gonzalez, Raul S.,Salaria, Safia N.,Bohannon, Caitlin D.,etc.PD-1 inhibitor gastroenterocolitis: case series and appraisal of 'immunomodulatory gastroenterocolitis'[J].2017,70(4).
[26]Carbone, D. P.,Reck, M.,Paz-Ares, L.,etc.First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer[J].2017,376(25).
[27]Naidoo, Jarushka,Wang, Xuan,Woo, Kaitlin M.,etc.Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy[J].2017,35(7).
[28]Brahmer, Julie,Reckamp, Karen L.,Baas, Paul,etc.Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer[J].2015,373(2).
[29]Pillai, Rathi N.,Behera, Madhusmita,Owonikoko, Taofeek K.,etc.Comparison of the Toxicity Profile of PD-1 Versus PD-L1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Analysis of the Literature[J].2018,124(2).
[30]Postow, Michael A.,Sidlow, Robert,Hellmann, Matthew D..Immune-Related Adverse Events Associated with Immune Checkpoint Blockade[J].2018,378(2).
[31]S. Champiat,O. Lambotte,E. Barreau,etc.Editor's choice: Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper[J].2016,(4).
[32]Wang, Daniel Y.,Salem, Joe-Elie,Cohen, Justine V.,etc.Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors A Systematic Review and Meta-analysis[J].2018,4(12).